Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Futures FTSE +0.27%, DAX +0.14%, CAC40 +0.21%

Dec 17 ,2025

  • Synopsis

    • European equity markets are set to open in positive territory. Asia equities mixed in choppy trading Wednesday. A small gain for the Nikkei 225 while the Topix is flat; gains for Greater China, South Korea and several Southeast Asia boards. Australia, Taiwan, India and Singapore lower. US futures trading slightly lower.

    • FT reports Germany's parliament is set to agree to more than €50bn in military purchases on Wednesday. Norway's PM Støre biannual summary press conf at 11:00CET. In UK, there's the last weekly PMQs at 12noon GMT before parliament breaks for the Christmas holidays, whilst committee topics include Railways Bill at 9:15, and revisiting the nuclear roadmap at 15:00. EU-Western Balkans summit, EU's von der Leyen and Kallas, Chancellor Merz among the participants

    • In central banks, SNB releases its latest quarterly report at 15:00CET. Greece's IOBE publishes 2026 economic estimates for 2026 (livestream) at 16:00CET.

    • Macro data include Germany Dec Ifo survey, UK Nov CPI/RPI.PPI input/output, Dec industrial trends orders - CBI, Austria Nov final CPI, Eurozone Nov final CPI

    • In earnings, Suedzucker (SZU.GR) confirms FY26 (Feb) guidance for adjusted EBITDA guidance €470-570M vs FactSet €490.6M and provides first FY27 outlook whilst IONOS Group (IOS.GR) now expects FY currency-adjusted revenue growth of ~ +6% vs previously ~ +8%. thyssenkrupp nucera (NCH2.GR) reports FY EPS €0.04 vs FactSet €0.07 and CECONOMY (CEC.GR) reports final FY earnings in line with prelim. release: EPS €0.13 vs FactSet €0.35.

    • VINCI (DGFP) and Aeroport de Paris (ADP.FP) are out with November traffic.

    • CMD/Events: Avacta Group (AVCT.LN) faridoxorubicin Phase 1B clinical trial results webinar (registration), Redcentric (RCN.LN) presenting via the Investor Meet Company platform at 10:00GMT

  • Politics/Macro/World News

    • EU Commission releases automotive package; postpones the ban on selling new cars with combustion engines

    • Germany set to approve €50B in military purchases - FT

    • Keir Starmer pushes back on delayed defence spending plan - FT

    • Merz and Weber deliver triumphant week for Europe's center right - politico

    • U.S. Threatens Penalties Against European Tech Firms Amid Regulatory Fight - The New York Times

    • Trump orders blockade of sanctioned oil tankers entering and exiting Venezuela - Truth Social

  • Top company news

    • Earnings/updates

      • DACHs:

        • SZU.GR (Suedzucker) -- reaffirms FY26 (Feb) adjusted EBITDA guidance €470-570M vs FactSet €490.6M [5 est, €457-520M]; provides first FY27 outlook

        • IOS.GR (IONOS Group) -- now expects FY currency-adjusted revenue growth of ~ +6% vs previously ~ +8%

        • NCH2.GR (thyssenkrupp nucera) -- reports FY EPS €0.04 vs FactSet €0.07 [9 est, €0.02-0.14]

        • CEC.GR (CECONOMY) -- reports final FY earnings in line with prelim. release: EPS €0.13 vs FactSet €0.35 [4 est, €0.20-0.44

      • France:

        • DG.FP (VINCI SA) -- reports Nov airport passenger traffic +2.9%

        • ADP.FP (Aeroport de Paris) -- reports Total Paris Aeroport November traffic 7.8M, +3.9% y/y

        • EAPI.FP (Euroapi) -- provides business update

      • Nordics:

        • VITR.SS (Vitrolife) -- announces genetic services restructuring program; recognizes SEK 5.4B goodwill impairment

    • M&A

      • CLCO.NO (Cool Co.) -- shareholders to vote on 6-Jan on proposed merger with newly formed, wholly owned subsidiary of EPS Ventures

      • CARR (Carrier Global) -- Carrier to Sell Riello to Ariston Group for gross proceeds of ~$430M

      • OPAP.GA (Greek Organisation of Football Prognostics) -- OPAP's EGM to approve the various steps of the merger agreement with Allwyn International will be held on 7-Jan-26; terms amended (post EU close 16-Dec)

      • PBR (Petrobras) -- reportedly set to sign deal to buy stake in BP's brazil solar and battery unit - Bloomberg

      • RI.FP (Pernod Ricard) -- and Trinchero in definitive agreement for the sale of Mumm Napa sparkling wines

      • CON.GR (Continental) -- seeking to sell mycar - Australian Financial Review

      • BARN.SW (Barry Callebaut) -- reportedly exploring separation of its cocoa business -- Reuters (earlier, intraday Switzerland)

      • EQT.SS (EQT AB) -- completes sale of shares in Enity Holding AB; received c. SEK 565M

      • LKOH.RU (Lukoil) -- Midad Energy emerges as leading contender to acquire Lukoil's international assets - Reuters

      • KOG.NO (Kongsberg Gruppen) -- acquires California-based missile company Zone 5 Technologies LLC; price undisclosed

      • DKSH.SW (DKSH Holding) -- acquires Biomedic Science Material Joint Stock Company in Vietnam; price undisclosed

      • STO.AU (Santos) -- divests 42.7% interest in Petrel fields and 100% interest in Tern fields to Eni Australia; terms undisclosed

      • AV.IM (Antares Vision) -- Crane NXT completes first phase of Antares Vision acquisition

      • AIRA.LN (Air Astana) -- BAE Systems intends to sell global depositary receipts of Air Astana Joint Stock Company

    • Healthcare

      • NYXH.BB (Nyxoah) -- announces commercial launch of Genio breakthrough therapy in the Netherlands

      • GSK.LN (GSK Plc) -- FDA approves Exdensur (depemokimab) for the treatment of severe asthma

      • SAN.FP (Sanofi) -- Sanofi's efdoralprine granted EU orphan drug designation for alpha-1-antitrypsin deficiency emphysema

      • DBV.FP (DBV Technologies) -- preliminary Phase 3 VITESSE study results of the VIASKIN Peanut patch in children aged 4 to 7 meets primary endpoint

      • GALD.SW (Galderma Group) -- announces new clinical data confirming nemolizumab's rapid onset of action on itch and sleep; data published in the Journal of the European Academy of Dermatology and Venereology

      • HNSA.SS (Hansa Biopharma) -- provides update on Pivotal Phase 3 trial in anti-glomerular basement membrane disease

    • Other

      • TERNOR.SS (Terranor Group) --Mutares SE & Co KGaA places 2.5M shares of its stake in Terranor Group AB; gross proceeds ~ €6M

      • NDX1.GR (Nordex) -- receives order for nearly 107 MW in North Rhine-Westphalia, Germany

      • ADMCM.FH (Admicom) -- announces changes in it's leadership team

      • SAGA.NO (Saga Pure) -- convenes shareholder requested EGM on 7-Jan-26

      • VAR.NO (Vår Energi) -- says has delivered on its commitment to complete nine out of nine growth projects in 2025

      • AIR.FP (Airbus SE) -- awarded $323.7M US Army contract modificatino

      • VWS.DC (Vestas Wind Systems) -- Vestas and Casa dos Ventos partnership receives 828 MW order for the Dom Inocêncio wind complex

      • ML.FP (Cie Generale des Etablissements Michelin SA) -- Michelin publishes global tire market data for Nov

      • UPM.FH (UPM-Kymmene) -- discontinues graphic paper production in Ettringen

      • ACA.FP (Credit Agricole) -- appoints Eric Vial as new Chairman effective 1-Jan-26

      • CABK.SM (CaixaBank) -- announces updated MREL requirement

      • KEMIRA.FH (Kemira) -- completes share buyback program announced in July 2025

      • EU releases proposal to abandon combusting engine ban after auto lobbying efforts in intraday themes (16-Dec)

      • Petrobras announces signing of strategic partnership in the renewable energy segment in Brazil

      • Regional Gaming Revenues - New Jersey November 2025

  • Key rating changes

    • Upgrades

      • Barclays upgrades LSG.NO, MOWI.NO, SALM.NO

      • Berenberg upgrades GLEN.LN; resumes ACG.LN

      • KeyBanc upgrades AHT.LN, HRI

      • HSBA.LN (HSBC Holdings) -- to outperform from market perform at Keefe, Bruyette & Woods

    • Downgrades

      • NAS.NO (Norwegian Air Shuttle) -- hold from buy at Pareto

      • ADP.FP (Aeroport de Paris) -- to hold from buy at Jefferies

    • Other Actions

      • ESSITY.B.SS (Essity) -- resumed buy at Pareto

      • HTG.LN (Hunting) -- transferred hold at Jefferies; prior rating was buy

  • Data

    • Nikkei +0.26% to 49512.28

    • Hang Seng +0.76% to 25426.35

    • Shanghai Composite +1.22% to 3871.52

    • S&P futures +6.3 vs prior close of 6856.3

    • €-$ (0.0034) or (0.29%) to 1.1715

    • $-¥ +0.68 or +0.44% to 155.41

    • €-¥ +0.24 or +0.13% to 182.00

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE